Overview
Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2021-10-31
2021-10-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
1. Metastatic gastric cancer patients who failed standard treatment will be enrolled in this study. 2. After consent form, patient-derived cancer cell will be collected and tested with 3 kinds of drugs (sunitinib, gefitinib, imatinib). 3. Drug sensitivity prediction software (IRCR-DReSS) will present level of sensitivity and patients will be treated with sensitive drugs. 4. Patients will be evaluated every 6 weeks.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Samsung Medical CenterTreatments:
Gefitinib
Imatinib Mesylate
Sunitinib
Criteria
Inclusion Criteria:- age>-20
- metastatic gastric cancer
- life expectancy >-3 months
- ascites and pleural effusion that can be drained
- ECOG 0-2
- Proper organ function
- Patients who will be enrolled in sunitinib, gefitinib, imatinib clinical trial
Exclusion Criteria:
- HBeAg, HCV, HIV (+)
- Active infection
- Uncontrolled systemic disease